All In MedTech

FDA Clearance Tracker · P100034-S018

Optune

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 30, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 30, 2018

Approved

Time to decision

178 days

Received Jun 5, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100034-S018
Device name
Optune
Applicant location
Baar
Received
Jun 5, 2018
Decided
Nov 30, 2018
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100034

Device type

Device class
Class III

Every decision under product code NZK

FDA's approval statement

As written in FDA's record.

Approval to update the Optune™ device labeling with the clinical outcome data from the pivotal study conducted to treat newly diagnosed glioblastoma (Long-Term EF-14).

Source documents

Other decisions for Novocure, GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.